Emergent starts phase 1 trial of Zika virus immune globulin therapeutic

This article was originally published here

ZIKV-IG was granted Fast Track designation by the U.S. Food and Drug Administration (FDA) in December 2017. Emergent BioSolutions senior vice president and antibody therapeutics business unit head

The post Emergent starts phase 1 trial of Zika virus immune globulin therapeutic appeared first on Pharma Business review.

0 replies

Leave a Reply

Want to join the discussion?
Feel free to contribute!

Leave a Reply